Completed OBSERVATIONAL NCT06040229

Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma

Mechanism of Children With Relapsed and Refractory Rhabdomyosarcoma (RMS)

Sponsor: Shandong First Medical University

Conditions Alveolar Childhood Rhabdomyosarcoma Embryonal Childhood Rhabdomyosarcoma Recurrent Childhood Rhabdomyosarcoma

Updated 3 times since 2023 Last updated: Sep 10, 2023 Started: Apr 1, 2023 Primary completion: Jul 1, 2023 Completion: Sep 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06040229, this observational or N/A phase trial focuses on Alveolar Childhood Rhabdomyosarcoma and Embryonal Childhood Rhabdomyosarcoma and remains completed. Sponsored by Shandong First Medical University, it has been updated 3 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Oct 2023 — Jul 2024 [monthly]

Completed

First recorded

Apr 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong First Medical University
Shandong Tumor Hospital

Data source: Shandong First Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China